Seladelpar · Livdelzi

Small molecule

Also known as MBX-8025

Approvedregulatory verdict

Evidence outlook

Approved: Primary Biliary Cholangitis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
CA
  • LYVDELZI (seladelpar) is indicated for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in adults unable to tolerate UDCA. Marketing authorization with conditions for this indication is based on a randomized, placebo-controlled, phase III study that assessed alkaline phosphatase (ALP) and bilirubin as a composite biochemical surrogate endpoint [see 14 CLINICAL TRIALS]. Continued approval for this indication is contingent upon verification of clinical benefit in a...
Product first approved 2025Health Canada
EU
  • Primary biliary cholangitis (PBC) with UDCA in adults with an inadequate response to UDCA, or as monotherapy in those unable to tolerate UDCA (Lyvdelzi, conditional)
Product first approved 2025EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Primary Biliary Cholangitis
NCT06051617 · Gilead Sciences
2023-09-07 – 2030-08 · Primary Biliary Cholangitis
What this study did
NCT03301506 · Gilead Sciences
2017-12-12 – 2028-12 · Primary Biliary Cirrhosis
What this study did
Phase 2 (8)
Primary Biliary Cholangitis
NCT07841977 · Gilead Sciences
2026-10-01 – 2034-06 · Primary Biliary Cholangitis
What this study did
NCT02955602 · Gilead Sciences
2016-11-28 – 2019-07-08 · Primary Biliary Cirrhosis
What this study did
Other / comorbidity
NCT07305363 · University of California, San Diego
2026-05 – 2027-12 · Liver Transplant; Complications, Ischemic Cholangiopathy
What this study did
NCT03551522 · Gilead Sciences
2018-04-30 – 2020-08-10 · NASH - Nonalcoholic Steatohepatitis
What this study did
NCT04024813 · Gilead Sciences
2019-11-12 – 2020-01-09 · Primary Sclerosing Cholangitis
What this study did
NCT02609048 · Gilead Sciences
2015-11-04 – 2016-07-01 · Primary Biliary Cirrhosis (PBC)
What this study did
NCT02472535 · Gilead Sciences
2015-04 – 2016-02 · Homozygous Familial Hypercholesterolemia
What this study did
NCT00701883 · Gilead Sciences
2007-08 – 2008-08 · Hyperlipidemia
What this study did
Phase 1 (2)
Primary Biliary Cholangitis
NCT04950764 · Gilead Sciences
2021-11-16 – 2025-02-27 · Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment
What this study did
Other / comorbidity
NCT03369002 · Gilead Sciences
2017-11-27 – 2018-05-15 · Hepatic Impairment
What this study did

Competitive landscape

This drug's own stage for Primary Biliary Cholangitis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Seladelpar (Livdelzi): this drugApprovedSmall moleculePPAR-deltaPartial signal
NCT06060665: Primary endpoint, composite ALP normalization at week 52: significantly more patients than placebo (Gilead, 2026-06-02).
NCT04620733: Composite biochemical response at Month 12 (ALP below 1.67 x ULN, ALP reduction of at least 15% and total bilirubin at or below ULN), seladelpar (n=128) vs placebo (n=65): 61.7% vs 20.0%; risk difference 41.7 percentage points (95% CI 27.7 to 53.4), p < 0.0001 (Cochran-Mantel-Haenszel; CT.gov posted results).
Elafibranor (Iqirvo)ApprovedSmall moleculePPAR-alpha/PPAR-deltaPartial signal
NCT04526665: Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52 (At Week 52): Elafibranor 80 mg 50.9 Percentage of participants (95% CI 41.6 to 60.2) | Placebo 3.8 Percentage of participants (95% CI 1 to 12.8)
Saroglitazar (Lipaglyn)Phase 3Small moleculePPAR-alpha/PPAR-gammaPartial signal
NCT05133336: Primary composite biochemical response at 52 weeks: treatment difference 48.5% favouring saroglitazar 1 mg over placebo (P<0.001) (2025-08-29).
Pemafibrate (Parmodia)Phase 2Small moleculePPAR-alphanot yet gradedNo reviewed efficacy summary in this indication
SetanaxibPhase 2Small moleculeNOX1/4not yet gradedNo reviewed efficacy summary in this indication
VolixibatPhase 2Small moleculeIleal bile acid transporter (IBAT)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Livdelzi (Seladelpar) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
Phase 2Liver Transplant; Complications, Ischemic CholangiopathyNot yet recruiting
Est. primary completion 2027-09 · NCT07305363 · CT.gov ↗
What to watch
2028 (2)
November 2028 (1)
Phase 3Primary Biliary CholangitisActive not recruiting
Est. primary completion 2028-11 · NCT03301506 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Primary Biliary CholangitisRecruiting
Est. primary completion 2028-12 · NCT07841977 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Phase 3Primary Biliary CholangitisRecruiting
Est. primary completion 2030-08 · NCT06051617 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 June 2026Topline resultIDEAL (NCT06060665) Phase 3 met its primary endpoint
Gilead Sciences, Inc. · Source ↗